No Data
No Data
Reported Sunday, Roche's Genentech Showcases Polivy's Transformative Impact On Frontline DLBCL Treatment: Five-Year POLARIX Trial Results Presented At ASH 2024
Kepler Capital Sticks to Their Buy Rating for Roche Holding AG (RHHVF)
FDA Accepts Roche's Columvi SBLA for Expanded Use in Lymphoma
Roche (RHHBY.US) CD20/CD3 bispecific antibody new indication application accepted by the FDA.
Roche (RHHBY.US) announced that the FDA has accepted the supplemental biological product license application (sBLA) for glofitamab.
FDA Accepts Genentech's SBLA For Columvi Combination Therapy For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Roche (RHHBY.US) reached a nearly 0.9 billion dollar collaboration to develop therapies for autoimmune diseases.
COUR Pharmaceuticals announced a strategic collaboration and licensing agreement with Genentech, a subsidiary of Roche (RHHBY.US).
Unlock the Full List